Related Experiment Video
Updated: Apr 12, 2026
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis
L Mestre1, M Redondo2, F J Carrillo-Salinas1
1Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal-CSIC, Madrid, Spain.
Background And Purpose:
cAMP plays an important role in the transduction of signalling pathways involved in neuroprotection and immune regulation. Control of the levels of this nucleotide by inhibition of cAMP-specific PDEs such as PDE7 may affect the pathological processes of neuroinflammatory diseases like multiple sclerosis (MS). In the present study, we evaluated the therapeutic potential of the selective PDE7 inhibitor, TC3.6, in a model of primary progressive multiple sclerosis (PPMS), a rare and severe variant of MS.
Experimental Approach:
Theiler's murine encephalomyelitis virus-induced demyelinated disease (TMEV-IDD) is one of the models used to validate the therapeutic efficacy of new drugs in MS. As recent studies have analysed the effect of PDE7 inhibitors in the EAE model of MS, here the TMEV-IDD model was used to test their efficacy in a progressive variant of MS. Mice were subjected to two protocols of TC3.6 administration: on the pre-symptomatic phase and once the disease was established.
Key Results:
Treatment with TC3.6 ameliorated the disease course and improved motor deficits of infected mice. This was associated with down-regulation of microglial activation and reduced cellular infiltrates. Decreased expression of pro-inflammatory mediators such as COX-2 and the cytokines, IL-1β, TNF-α, IFN-γ and IL-6 in the spinal cord of TMEV-infected mice was also observed after TC3.6 administration.
Conclusion:
These findings support the importance of PDE7 inhibitors, and specifically TC3.6, as a novel class of agents with therapeutic potential for PPMS. Preclinical studies are needed to determine whether their effects translate into durable clinical benefits.
Insights
The PDE7 inhibitor TC3.6 showed therapeutic potential for primary progressive multiple sclerosis (PPMS) by reducing disease severity and inflammation in a mouse model. Further preclinical studies are needed to confirm these promising findings for neuroinflammatory diseases.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Cyclic adenosine monophosphate (cAMP) is crucial for neuroprotection and immune regulation.
- Phosphodiesterase 7 (PDE7) regulates cAMP levels and is implicated in neuroinflammatory diseases like multiple sclerosis (MS).
Purpose of the Study:
- To evaluate the therapeutic potential of the selective PDE7 inhibitor TC3.6.
- To investigate TC3.6 efficacy in a mouse model of primary progressive multiple sclerosis (PPMS).
Main Methods:
- Utilized the Theiler's murine encephalomyelitis virus-induced demyelinated disease (TMEV-IDD) model for PPMS.
- Administered TC3.6 pre-symptomatically and after disease onset in mice.
Main Results:
- TC3.6 treatment improved motor function and ameliorated disease progression in infected mice.
- Observed reduced microglial activation, decreased cellular infiltrates, and lower pro-inflammatory mediator expression (COX-2, IL-1β, TNF-α, IFN-γ, IL-6) in the spinal cord.
Conclusions:
- PDE7 inhibitors, particularly TC3.6, represent a promising therapeutic strategy for PPMS.
- Further preclinical research is warranted to assess the translation of these effects into clinical benefits for neuroinflammatory conditions.
More Related Videos
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
08:18A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
Published on: December 26, 2015
